Starpharma Interim Report and Half-Year Financial Results
Starpharma today released its interim report and financial results for the half-year ended 31 December 2017.
Starpharma receives $3.7M R&D tax incentive refund
Starpharma today announced that it has received a $3.7M R&D tax incentive refund associated with FY17 expenditures. The refund relates to eligible R&D expenditure across Starpharma’s portfolio, including VivaGel® and DEP® programs.
Shareholder Update February 2018
In this issue:
>> New sites open for the DEP® docetaxel phase 2 trial
>> DEP® cabazitaxel phase 1 / 2 trial commences
>> VivaGel® BV NDA submission lodged under Fast Track program
>> VivaGel® BV approved by TGA
>> DEP® irinotecan progressing towards the clinic
>> AstraZeneca-Starpharma collaboration
>> Extensive global licensing negotiations for VivaGel® BV
>> Positive market research findings for VivaGel® BV
>> Q2 Cashflow Report at 31 December 2017
>> OTCQX market recognition
>> Starpharma News & Events
>> Outlook
Download: Shareholder Update February 2018 (pdf file, 1.5mb)